Last updated: 2026-09-05 16:19:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Assembly Biosciences, Inc. (ASMB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $36.65, with a market capitalisation of $747.64M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $20.23 to $39.71. This page covers its latest market performance, valuation, price trends and company information.
$747.64M | |
$35.68 | |
$808.32 | |
$7.69 | |
$36.13 | |
133.02K | |
-- | |
-- | |
$39.71 | |
$20.23 | |
-- | |
-- |
Assembly Biosciences, Inc. (ASMB) last closed at $36.13 as of 2026-09-04 23:31:00, unchanged from the previous close of $36.13.
During the latest regular trading session, ASMB traded between $7.69 and $808.32, with a volume of 133.02K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Assembly Biosciences, Inc. (ASMB) moved from $33.80 to $36.65, representing a gain of 8.44% ($2.85).
The stock traded between $35.56 and $36.92 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 232.60 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 84.3%
ASMB is currently trading at $36.65, placing it 84.3% of the way from its 52-week low of $20.23 to its 52-week high of $39.71. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Assembly Biosciences, Inc. (ASMB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.